BMRN catalyst calendar

BIOMARIN PHARMACEUTICAL INC

Upcoming catalysts
14
Cash runway
Cash generating
Cash & investments
$874M
Phase 3 programs
12

BIOMARIN PHARMACEUTICAL INC is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.

The next scheduled catalyst is Next quarterly earnings (projected) on December 6, 2026, a projected date rather than a confirmed one. There are 14 upcoming events on record.

BIOMARIN PHARMACEUTICAL INC generates cash from operations, so a burn-based runway figure does not apply.

Across 81 concluded trials, 75% reached completion rather than being terminated or withdrawn.

Upcoming catalysts

DateEventTypePhase
December 6, 2026 est. Next quarterly earnings (projected) Earnings —
March 15, 2027 A Study of Vosoritide in Children With Noonan Syndrome With Inadequate Growth During or After Human Growth Hormone Treatment Trial Milestone Phase 2
April 14, 2027 A Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMN 351 in Participants With Duchenne Muscular Dystrophy Trial Milestone Phase 1/Phase 2
September 30, 2027 Immune Modulation During Palynziq® Treatment in Adults (IMPALA) Trial Milestone Phase 4
December 15, 2027 A Clinical Trial to Evaluate Safety of Vosoritide in At-risk Infants With Achondroplasia Trial Milestone Phase 2
December 15, 2027 A Study to Evaluate Long-Term Safety, Tolerability, & Efficacy of BMN 111 in Children With Achondroplasia (ACH) Trial Milestone Phase 2
December 15, 2027 AAV Gene Therapy Study for Subjects with PKU Trial Milestone Phase 1/Phase 2
June 30, 2028 A Study of Vosoritide Versus Placebo in Children With Hypochondroplasia Aged 0 to < 36 Months Trial Milestone Phase 2
November 15, 2028 A Gene Therapy Study of BMN 331 in Subjects With Hereditary Angioedema Trial Milestone Phase 1/Phase 2
June 15, 2029 Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With Achondroplasia Trial Milestone Phase 2/Phase 3
June 15, 2031 An Extension Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia Trial Milestone Phase 3
December 15, 2031 An Open-Label Extension Study to Evaluate the Long-term Safety and Efficacy of BMN 351 in Participants With Duchenne Muscular Dystrophy Trial Milestone Phase 2
May 15, 2038 An Extension Study to Evaluate Safety and Efficacy of BMN 111 in Children With Achondroplasia Trial Milestone Phase 2
October 15, 2044 Long-Term Extension Study of Vosoritide to Treat Children With Hypochondroplasia Trial Milestone Phase 3

Track BMRN alongside other companies. Add it to a watchlist and see every catalyst on one calendar.

Open BMRN in the tracker

Recent history

DateEventTypePhase
October 6, 2026 Quarterly results filed (8-K) Earnings —
September 30, 2026 8-K filed: Material agreement Corporate —
September 15, 2026 8-K filed: Other event Filing —
September 14, 2026 8-K filed: Leadership change Corporate —
September 1, 2026 8-K filed: Other event Filing —
August 31, 2026 8-K filed: Material agreement, Reg FD disclosure Corporate —
August 19, 2026 Study of BMN 349 Single Dose in PiZZ and PiMZ/MASH Adult Participants Trial Milestone Phase 1
August 18, 2026 8-K filed: Material agreement, Reg FD disclosure Corporate —
August 17, 2026 Rapid Drug Desensitization Study in Adults Experiencing Hypersensitivity Reactions to Palynziq Trial Milestone Phase 4
August 6, 2026 Quarterly results filed (8-K) Earnings —
August 1, 2026 Interventional Study of Vosoritide for the Treatment of Children With Hypochondroplasia Trial Milestone Phase 3
July 13, 2026 8-K/A filed: Other event Filing —
June 15, 2026 A Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature Trial Milestone Phase 2
June 4, 2026 8-K filed: Leadership change Corporate —
May 4, 2026 Quarterly results filed (8-K) Earnings —
April 27, 2026 8-K filed: Material agreement, Acquisition completed, Reg FD disclosure Corporate —
April 23, 2026 8-K filed: Other event Filing —
April 20, 2026 Safety, Tolerability, and Efficacy Study of Valoctocogene Roxaparvovec in Hemophilia A With Active or Prior Inhibitors Trial Milestone Phase 1/Phase 2
March 16, 2026 8-K filed: Other event Filing —
February 23, 2026 Quarterly results filed (8-K) Earnings —
February 12, 2026 8-K filed: Material agreement, Reg FD disclosure Corporate —
January 29, 2026 8-K filed: Reg FD disclosure Filing —
January 26, 2026 Quarterly results filed (8-K) Earnings —
January 12, 2026 Quarterly results filed (8-K) Earnings —
December 22, 2025 8-K filed: Other event Filing —
December 19, 2025 8-K filed: Material agreement, Reg FD disclosure Corporate —
December 17, 2025 8-K filed: Leadership change Corporate —
October 27, 2025 Quarterly results filed (8-K) Earnings —
October 7, 2025 Quarterly results filed (8-K) Earnings —
August 11, 2025 8-K filed: Leadership change Corporate —

About this data

Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.

Last updated 2026-10-14.